Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY)

seekingalpha.com · 2026-09-04

Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.

Read the full story at seekingalpha.com →